EGFR and non-small cell lung carcinoma: Therefore, our findings strongly suggest considering a combination of mutation detection assays as the molecular screening approach of choice for routine assessment of EGFR mutational status based on ctDNA in NSCLC patients aimed at providing guidance toward the appropriate treatment strategy.